Drawing for EXIANT

USPTO serial 88381334

EXIANT

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
VERHOSEK, WILLIAM T
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EXIANT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Louis C. Cullman

Louis C. Cullman K&L GATES LLP1 PARK PLAZA, 12TH FLOORIRVINE, CA 92614UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, stomach, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders for use in oncology; pharmaceutical mineral supplements and preparations for use in oncology; none of the foregoing for diagnostic useACTIVE—
009Downloadable software for the facilitation of communication, namely, allowing patients and healthcare professionals to access and share information in the medical, pharmaceutical and health fields; downloadable software in the nature of a mobile application for facilitation of communication, namely, allowing patients and healthcare professionals to access and share information in the medical, pharmaceutical and health fields; none of the foregoing for diagnostic useACTIVE—
010Drug delivery devices in the nature of drug delivery systems; drug delivery systems; injection device for pharmaceutical preparations; injectors for medical purposes in the nature of medical fluid injectors; none of the foregoing for diagnostic useACTIVE—
035Online wholesale services by direct solicitation by salespersons directed to end-users featuring pharmaceuticals; referral services in the field of treatment for cancer, chemotherapy and pharmaceutical products in the nature of medical referrals; business administration of prescription drug co-payment programs; business administration of patient reimbursement programs; referral services in the field of co-pay assistance programs in the nature of providing insurance agent referrals; providing an online commercial information directory in the field of patient support featuring information regarding healthcare providers, sites at which subcutaneous injections could be administered and retail pharmacies or specialty pharmacies where patients could obtain pharmaceutical preparations; none of the foregoing relating to diagnostic products or diagnosticsACTIVE—
036Providing healthcare administration, namely, providing insurance verification and prior authorization services for others; none of the foregoing relating to diagnostic products or diagnostics; none of the foregoing relating to diagnostic products or diagnosticsACTIVE—
041Educational services, namely, development and dissemination of printed educational materials of others in the fields of pharmaceutical products and treatment of medical disorders; conducting classes, seminars, conferences, and workshops in the field of the use of prescription pharmaceutical products for medical disorders, in the field of cancer, patient care; educational and entertainment services, namely, providing a motivational and educational speaker featuring information regarding medical disorders; training services in the field of patient support services relating to treatment of medical disorders; providing on-line electronic newsletters delivered by email, and blogs in the medical, pharmaceutical and health fields; none of the foregoing relating to diagnostic products or diagnosticsACTIVE—
042Medical and pharmaceutical research services; pharmaceutical research and development; none of the foregoing relating to diagnostic products or diagnosticsACTIVE—
044Patient support services relating to the treatment of medical disorders, namely, providing online information in the field of pharmaceutical preparations for treatment of various diseases and providing medical consultancy and advisory services via a global computer network; providing health and medical information about medical disorders; information services, namely, providing medical information to cancer patients; providing patient support services relating to cancer and cancer treatment in the nature of an Internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; providing a website featuring information in the medical and health fields; providing a website featuring information in the field of the prophylactic and therapeutic properties of pharmaceuticals; providing information in the medical field and information in the field of the prophylactic and therapeutic properties of pharmaceuticals; providing health information; providing patients with information in the medical field; providing health information, namely, providing data on the genetics and genetic sequencing of cancer tumors and cells; none of the foregoing relating to diagnostic products or diagnosticsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Nov 27, 2023MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 27, 2023ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 9, 2023ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
May 5, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 4, 2023EX5GSOU EXTENSION 5 GRANTED—
May 3, 2023AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 27, 2023EXT5SOU EXTENSION 5 FILED—
Apr 27, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 29, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 27, 2022EX4GSOU EXTENSION 4 GRANTED—
Oct 27, 2022EXT4SOU EXTENSION 4 FILED—
Oct 27, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 28, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 26, 2022EX3GSOU EXTENSION 3 GRANTED—
Apr 26, 2022EXT3SOU EXTENSION 3 FILED—
Apr 26, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 28, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 26, 2021EX2GSOU EXTENSION 2 GRANTED—
Oct 26, 2021EXT2SOU EXTENSION 2 FILED—
Oct 26, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 29, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 27, 2021EX1GSOU EXTENSION 1 GRANTED—
Apr 27, 2021EXT1SOU EXTENSION 1 FILED—
Apr 27, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 27, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 17, 2020CHPBPOST PUBLICATION AMENDMENT - ENTERED—
Sep 16, 2020APETASSIGNED TO PETITION STAFF—
Aug 20, 2020ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Aug 10, 2020EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Mar 11, 2020ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Feb 11, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 11, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 22, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 6, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 24, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 23, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 23, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 24, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 24, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 24, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 21, 2019DOCKASSIGNED TO EXAMINER—
Apr 29, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 15, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance